Pacira Pharmaceuticals (NASDAQ:PCRX) had its price target raised by investment analysts at BMO Capital Markets from $31.00 to $34.00 in a research note issued on Monday. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 1.64% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. Canaccord Genuity dropped their price target on shares of Pacira Pharmaceuticals from $46.00 to $42.00 and set a “hold” rating for the company in a research report on Tuesday, January 30th. Oppenheimer reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday, February 15th. HC Wainwright reiterated a “buy” rating and issued a $48.00 price target (up from $45.00) on shares of Pacira Pharmaceuticals in a research report on Monday. Royal Bank of Canada set a $44.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 1st. Finally, Barclays reiterated a “buy” rating and issued a $40.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $44.35.
Shares of NASDAQ:PCRX traded down $1.10 during trading on Monday, reaching $33.45. 1,628,686 shares of the stock were exchanged, compared to its average volume of 1,212,933. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96. Pacira Pharmaceuticals has a 12 month low of $26.95 and a 12 month high of $52.47.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The company had revenue of $79.08 million during the quarter, compared to the consensus estimate of $79.06 million. During the same period in the previous year, the business earned $0.09 earnings per share. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. analysts expect that Pacira Pharmaceuticals will post -0.51 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in PCRX. Rice Hall James & Associates LLC grew its stake in shares of Pacira Pharmaceuticals by 18.4% during the fourth quarter. Rice Hall James & Associates LLC now owns 323,769 shares of the company’s stock worth $14,780,000 after buying an additional 50,335 shares during the last quarter. Mesirow Financial Investment Management Equity Management grew its stake in shares of Pacira Pharmaceuticals by 5.1% during the fourth quarter. Mesirow Financial Investment Management Equity Management now owns 410,561 shares of the company’s stock worth $18,742,000 after buying an additional 19,876 shares during the last quarter. Legacy Capital Partners Inc. grew its stake in shares of Pacira Pharmaceuticals by 6.5% during the fourth quarter. Legacy Capital Partners Inc. now owns 50,493 shares of the company’s stock worth $2,305,000 after buying an additional 3,100 shares during the last quarter. HealthCor Management L.P. grew its stake in shares of Pacira Pharmaceuticals by 8.6% during the fourth quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock worth $127,820,000 after buying an additional 221,960 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its stake in shares of Pacira Pharmaceuticals by 35.9% during the fourth quarter. State of Wisconsin Investment Board now owns 39,400 shares of the company’s stock worth $1,799,000 after buying an additional 10,400 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “BMO Capital Markets Increases Pacira Pharmaceuticals (PCRX) Price Target to $34.00” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/13/pacira-pharmaceuticals-pcrx-price-target-raised-to-34-00-at-bmo-capital-markets.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.